DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates

Core Insights - DarioHealth Corp. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and a decline from earnings of $0.06 per share a year ago, indicating an earnings surprise of -9.09% [1] - The company generated revenues of $5.37 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 22.19% and down from $6.26 million year-over-year [2] - DarioHealth shares have decreased by approximately 36% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.07 on revenues of $8.52 million, and for the current fiscal year, it is -$0.32 on revenues of $32.24 million [7] Industry Context - The Medical - Instruments industry, to which DarioHealth belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting that the industry's outlook could significantly impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]